HEC 72702) manufacturers
- HEC72702
-
- $2580.00
-
2026-04-21
- CAS:1793063-59-8
- Purity:
- Supply Ability: 10g
|
| | HEC 72702) Basic information |
| Product Name: | HEC 72702) | | Synonyms: | HEC 72702);HEC72702
(HEC-72702;2-Morpholinepropanoic acid, 4-[[(6R)-6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-(2-thiazolyl)-4-pyrimidinyl]methyl]-, (2R)- | | CAS: | 1793063-59-8 | | MF: | C24H26BrFN4O5S | | MW: | 581.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1793063-59-8.mol |  |
| | HEC 72702) Chemical Properties |
| Boiling point | 669.0±65.0 °C(Predicted) | | density | 1.60±0.1 g/cm3(Predicted) | | pka | 4.50±0.10(Predicted) |
| | HEC 72702) Usage And Synthesis |
| Uses | HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC50 values of 0.039 μM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers[1]. | | in vivo | HEC72702 (50, 100 mg/kg; p.o.; daily for 7 days) dose-dependently reduces HBV DNA in both the plasma and livers copies[1].
Pharmacokinetic Parameters of HEC72702 in Male Sprague-Dawley rats[1].
| dose (mg/kg) | iv (2) | po (5) | | AUC(0-24 h) (h*ng/mL) | 4110 | 4900 | | CL (mL/min/kg) | 8.11 | | | VSS (L/kg) | 0.41 | | | F % | | 47.7 |
Male Sprague-Dawley rats, 2 mg/kg iv; 5 mg/kg po [1].
| Animal Model: | 6-7 weeks, 16-18 g, Female BALB/c mice(HDI mouse model)[1] | | Dosage: | 50, 100 mg/kg | | Administration: | P.o.; daily for 7 days | | Result: | Demonstrated a dose-dependent reduction of HBV DNA in the plasma of infected mice. |
| | References | [1] Ren Q, et al. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4. J Med Chem. 2018 Feb 8;61(3):1355-1374. DOI:10.1021/acs.jmedchem.7b01914 |
| | HEC 72702) Preparation Products And Raw materials |
|